이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Femasys 관리

관리 기준 확인 2/4

Femasys' CEO는 Kathy Lee-Sepsick, Feb2004 에 임명되었습니다 의 임기는 20.33 년입니다. 총 연간 보상은 $ 1.02M, 49% 로 구성됩니다. 49% 급여 및 51% 보너스(회사 주식 및 옵션 포함). 는 $ 334.25K 가치에 해당하는 회사 주식의 1.58% 직접 소유합니다. 334.25K. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 8.7 년입니다.

주요 정보

Kathy Lee-Sepsick

최고 경영자

US$1.0m

총 보상

CEO 급여 비율	49.0%
CEO 임기	20.3yrs
CEO 소유권	1.6%
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	8.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Kathy Lee-Sepsick 의 보수는 Femasys 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$1m	US$500k	-US$14m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$659k	US$423k	-US$11m
Sep 30 2022	n/a	n/a	-US$11m
Jun 30 2022	n/a	n/a	-US$10m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$567k	US$540k	-US$8m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$7m
Dec 31 2020	US$307k	US$280k	-US$7m

보상 대 시장: Kathy 의 총 보상 ($USD 1.02M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Kathy 의 보상이 증가했습니다.

CEO

Kathy Lee-Sepsick (56 yo)

20.3yrs

테뉴어

US$1,019,425

보상

Ms. Kathy Lee-Sepsick M.B.A, is Founder of Femasys Inc. and has been its Chief Executive Officer and President since February 2004. She served as Chairman of Board of Femasys Inc. since February 2004 until...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kathy Lee-Sepsick	Founder	20.3yrs	US$1.02m	1.58% $ 402.5k
Dov Elefant	Chief Financial Officer	2.3yrs	US$716.22k	0% $ 0
Daniel Currie	COO, Senior VP & Secretary	20.4yrs	US$630.42k	0.40% $ 103.1k
Mary Merchant	Vice President of Counsel & Intellectual Property	no data	데이터 없음	데이터 없음
Sue Owens	Vice President of Sales	no data	데이터 없음	데이터 없음
Naomi Phaneuf	Vice President of Marketing	no data	데이터 없음	데이터 없음
Jeffrey Marcus	Chief Medical Advisor	no data	데이터 없음	데이터 없음
Christine Thomas	Senior VP of Regulatory & Clinical Affairs	1.7yrs	데이터 없음	데이터 없음
James Liu	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Richard Spector	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: FEMY 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kathy Lee-Sepsick	Founder	20.3yrs	US$1.02m	1.58% $ 402.5k
Charles Larsen	Independent Non-Executive Chairman of Board	8.7yrs	US$108.93k	0.14% $ 36.2k
Joshua Silverman	Independent Director	less than a year	US$5.00k	데이터 없음
Edward Uzialko	Independent Director	18.8yrs	US$41.97k	5.48% $ 1.4m
Alistair Milnes	Independent Director	less than a year	US$31.44k	0.025% $ 6.5k

8.7yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: FEMY 의 이사회는 경험(평균 재직 기간 8.7 년)으로 간주됩니다.

Femasys 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Femasys Inc., Annual General Meeting, Jul 12, 2024

Femasys Inc. Appoints Richard Spector as Chief Commercial Officer

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Femasys Inc. Appoints Joshua Silverman as Director

Femasys Inc. Designates Daniel Currie as its Chief Operating Officer

Femasys Inc. Announces Management Changes

Recent updates

Femasys Inc., Annual General Meeting, Jul 12, 2024

Consensus revenue estimates decrease by 17%, EPS upgraded

Price target increased by 8.1% to US$10.00

New major risk - Financial position

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 13%

Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt?

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

New major risk - Share price stability

Femasys Inc. Appoints Richard Spector as Chief Commercial Officer

Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center, A Hub for Innovation and Groundbreaking Research in Health Care for Women

Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At University of Utah

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors

Femasys Inc. Appoints Joshua Silverman as Director

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 11%

New major risk - Revenue and earnings growth

Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation

Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation

Femasys Inc. Obtains Medical Device Establishment License from Health Canada

New major risk - Revenue and earnings growth

Femasys Inc. Designates Daniel Currie as its Chief Operating Officer

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Femasys Inc. Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, A Non-Surgical Alternative for Women

Femasys Inc. Announces Management Changes

Femasys' FemCath Intrauterine Catheter Receives Product Approval in Canada

Femasys Receives a Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$0.93 loss, revenue downgraded

Femasys Inc., Annual General Meeting, Jun 21, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Inc.'s FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada

Consensus EPS estimates fall by 32%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device

Femasys Inc. Reports Encouraging Promotional Launch of Femcerv At AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons

Femasys Inc. Completes Over 25% of its Targeted Enrollment in its FemaSeed De Novo Trial

Price target decreased to US$7.33

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Femasys Inc. Provides Strategic Update on FemaSeed Pivotal Trial Design to Expedite Clinical Program Advancement

Femasys Inc. Appoints Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs, Effective October 10, 2022

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

Femasys Inc. Announces Commercial Availability of FemCerv®

Femasys commercially launches Femcerv for cervical cancer screening

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M

Femasys Inc. Announces Board Changes

We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Femasys Inc. Appoints Dov Elefant to Chief Financial Officer, Effective February 28, 2022

Insufficient new directors

Femasys: Revolutionizing Female Reproduction

Independent Director recently bought US$172k worth of stock

Femasys Inc. has completed an IPO in the amount of $34.45 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령